Whole genome power.
Whole patient impact.
Curated whole genome insights. Actionable answers.
What we do
We unlock the power of the whole genome at scale, breaking through technology and cost barriers to make genomic insights accessible to everyone.
Generate data with the latest sequencing technologies
Create insights by turning data into action with our advanced AI and bioinformatics
Deliver testing for patients that captures what others might have missed
Accelerate research by integrating genomic insights with clinical data to drive innovation
Who we serve
Researchers
Maximize research potential and accelerate drug discovery and development.
Providers
Gain in-depth, clinically actionable insights to empower confident decision-making.
Patients
Turn uncertainty into clarity and find personalized insights.
See the whole genome, see what others miss
Whole genome offers a comprehensive view of the entire genome, uncovering mutations often overlooked by other types of tests.
> 25%
of cancer patients have complicated mutations that are often missed by other types of genetic tests.1
Our whole genome tests
CancerVision
Target-enhanced whole genome sequencing test that profiles solid tumor cancers.
- 2 in 1: Somatic + germline paired test
- Accurate: >99% sensitivity/positive predictive value + accurate complex variants detection (SV, CNV, non-coding areas)
- More insights: TMB, MSI, HRD, mutational signatures, germline variant detection
- Additional support: Clinical trial matching and genetic counseling
- CAP/CLIA assay, 2 week turnaround time
MRDVision
Whole-genome, tumor-informed ctDNA test for minimal disease detection.
- Ultra-sensitive: Limit of detection as low as 1 ppm (LOD95)*
- Whole-genome, panel-free approach, capturing rare variants in a complex tumor environment
- CAP/CLIA assay, 2 week turnaround time
*At simulated >10,000 mutations, 100x read-depth
RareVision
Whole-genome test that supports the diagnosis of rare diseases.
- Comprehensive test: Genes associated with 5,000+ rare diseases
- In-depth analysis, covering SNV, Indel, CNV, SV, non-coding areas
- Positive, inconclusive and secondary findings based on ACMG/ClinGen guideline and standards
- Additional support: Genetic counseling
- CAP/CLIA assay, 2 week turnaround time
